SIBO: Breath Testing, Rifaximin Protocols
& the IBS Connection Explained

What Is SIBO and Why Does It Matter?

Small intestinal bacterial overgrowth (SIBO) occurs when bacteria that normally populate the colon migrate into and colonize the small intestine. The small intestine is supposed to maintain a relatively low bacterial load — fewer than 10³ colony-forming units per milliliter. When this threshold is exceeded, the resulting fermentation and immune activation drives a cascade of symptoms that overlap extensively with irritable bowel syndrome.

The landmark discovery came in 2000 when gastroenterologist Mark Pimentel at Cedars-Sinai Medical Center began systematically testing IBS patients for SIBO using lactulose breath testing. His 2003 publication in the American Journal of Gastroenterology changed how researchers understood the IBS-gut bacteria connection: 78% of IBS patients tested positive for bacterial overgrowth, and antibiotic treatment targeting SIBO produced a 91% symptom improvement rate in those who normalized their breath test.

This wasn't a microbiome story about diversity or dysbiosis — it was a structural problem. Bacteria that belong downstream had moved upstream, fermenting food substrates that should have been absorbed before reaching the colon, producing gas, triggering motility dysfunction, and in some cases damaging the intestinal epithelium itself.

The Two Phenotypes: Hydrogen vs Methane SIBO

SIBO is not a single condition. The dominant gas produced during fermentation determines the clinical presentation, symptom pattern, and crucially, the treatment protocol.

Hydrogen-Dominant SIBO (H2-SIBO)

Hydrogen gas is produced by bacteria (primarily Escherichia coli, Klebsiella, Streptococcus, and various anaerobes) that ferment carbohydrates in the small intestine. Hydrogen-dominant SIBO classically presents with:

• Diarrhea-predominant or alternating bowel habits
• Bloating that worsens progressively through the day
• Abdominal cramping 30–90 minutes after eating
• Malabsorption of fats and fat-soluble vitamins in severe cases
• Elevated fasting breath hydrogen (>20 ppm baseline indicates significant dysbiosis)

Methane-Dominant SIBO (Intestinal Methanogen Overgrowth)

Methanogens — specifically Methanobrevibacter smithii — are not bacteria at all but archaea. They consume hydrogen produced by bacteria and convert it to methane (CH4). This creates a different fermentation ecosystem with distinct clinical consequences. Methane itself slows gut motility: it activates the ENS (enteric nervous system) in a way that mimics opioid receptor activation, dramatically slowing intestinal transit.

• Constipation-predominant symptoms (slow transit, difficult evacuation)
• Breath methane ≥10 ppm at any point during testing is diagnostic
• Greater bloating and abdominal distension post-meal
• Elevated methane correlates with harder stool consistency
• Requires combination antibiotic therapy — rifaximin alone is ineffective against archaea

Breath Testing: Lactulose vs Glucose

Breath testing remains the practical diagnostic standard for SIBO — it's non-invasive, relatively inexpensive, and can identify both hydrogen and methane producers. But the substrate matters enormously, and misinterpreting results is one of the most common clinical errors.

Lactulose Breath Test

Lactulose is a non-absorbable disaccharide. After ingestion, it travels the entire length of the small intestine before reaching the colon. Because it's not absorbed, it acts as a substrate for any bacteria present anywhere along the small bowel — making it theoretically better for detecting distal small intestinal overgrowth.

Positive criteria (North American Consensus 2017):

• Rise in breath hydrogen ≥20 ppm above baseline within the first 90 minutes
• Dual peak pattern: early peak (SIBO) followed by colonic peak at 120+ minutes
• Any methane reading ≥10 ppm at any point during the test

The critical interpretive challenge: the colonic fermentation peak typically arrives around 90–120 minutes. An early rise (before 90 minutes) suggests bacterial fermentation in the small intestine. A single late peak without early rise is likely colonic, not SIBO. Many practitioners incorrectly call any early rise positive without verifying timing thresholds.

Glucose Breath Test

Glucose is absorbed rapidly in the proximal small intestine. This means the glucose breath test only detects SIBO in the first 1–2 feet of small bowel. Its advantages: extremely high specificity (few false positives), simpler interpretation. Its limitation: significant sensitivity gap for mid or distal SIBO, which is common.

Positive criteria: Rise in breath hydrogen ≥12–20 ppm above baseline (lab-dependent) within 90 minutes of glucose ingestion.

Hydrogen Sulfide SIBO — The Emerging Third Phenotype

Hydrogen sulfide (H2S) is produced by sulfate-reducing bacteria and wasn't measurable on standard breath tests until the Trio-Smart test was developed. H2S-SIBO presents with a unique symptom complex: "rotten egg" gas, diarrhea, and paradoxically low or flat hydrogen readings on standard tests (sulfate reducers consume hydrogen, producing H2S instead — creating "flat-line SIBO" where standard tests appear normal).

The MMC: Root Cause of SIBO Recurrence

Understanding why SIBO keeps coming back requires understanding the migrating motor complex (MMC) — the physiological "housekeeper" of the small intestine.

During fasting, the MMC generates powerful peristaltic waves every 90–120 minutes that sweep bacteria, undigested food particles, and debris from the small intestine into the colon. This mechanism is why we're not supposed to continuously eat — the MMC only activates during fasting intervals. Mark Pimentel's research group identified that MMC dysfunction is a primary driver of SIBO development and recurrence.

What disrupts the MMC?

• Food poisoning (most common cause): Toxins from Campylobacter, Salmonella, and E. coli trigger production of anti-CdtB antibodies that cross-react with vinculin, a protein essential for MMC signaling. This creates a post-infectious, permanent MMC dysfunction in genetically susceptible individuals — explaining why SIBO often begins after a bout of "travelers diarrhea" or food poisoning.
• Opioid use: Opioids directly suppress the MMC — explaining high rates of SIBO in chronic opioid users
• Proton pump inhibitors: Gastric acid is a first-line defense against bacterial colonization; PPI suppression increases SIBO risk ~2-fold
• Hypothyroidism: Thyroid hormones regulate gut motility; hypothyroid states significantly impair MMC function
• Adhesions and structural abnormalities: Post-surgical adhesions, strictures, and anatomical abnormalities create stasis zones where bacteria accumulate

Pimentel 2003: The IBS-SIBO Connection

The most consequential SIBO research of the past two decades came from Mark Pimentel's group at Cedars-Sinai. In a 2003 American Journal of Gastroenterology study, they enrolled 202 consecutive IBS patients and 40 healthy controls, testing all with lactulose breath testing.

Results that reshaped gastroenterology:

• 78% of IBS patients had positive lactulose breath tests vs 40% of healthy controls
• Normalization of the breath test with antibiotics correlated with IBS symptom improvement: 91% of patients who eradicated SIBO showed symptom improvement
• IBS patients who did not normalize their breath test showed only 22% improvement — similar to placebo rates in IBS trials
• This correlation suggested SIBO isn't just a comorbidity in IBS but potentially a causative mechanism

The 2011 TARGET 1 and TARGET 2 trials confirmed the clinical relevance: rifaximin 550mg TID × 14 days produced significantly higher rates of global IBS symptom relief vs placebo in diarrhea-predominant IBS (40.7% vs 31.7% for global relief; p=0.01). Rifaximin was subsequently FDA-approved for IBS-D in 2015 under the brand name Xifaxan.

Treatment Protocols: Matching Phenotype to Antibiotic

Dietary Approaches During and After Treatment

Diet cannot cure SIBO but significantly impacts symptom burden during treatment and bacterial load before eradication is complete.

Low-FODMAP Diet

FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) are the primary substrates that gut bacteria ferment. A strict low-FODMAP diet during antibiotic treatment reduces symptoms by starving bacteria of fermentable substrates — but it doesn't eradicate SIBO. Monash University's low-FODMAP app provides the most comprehensive and evidence-based food guides.

Specific Carbohydrate Diet (SCD) / GAPS

More restrictive than low-FODMAP, eliminating all complex carbohydrates. Used by some SIBO practitioners to create a more hostile environment for bacteria during treatment. Lacks robust RCT evidence in SIBO specifically but has supportive case series data.

Bi-Phasic Diet Protocol (Nirala Jacobi)

A structured approach combining low-FODMAP with anti-bacterial dietary principles. Phase 1 (weeks 1–4): reduce bacterial load through dietary restriction. Phase 2 (weeks 5–8): continue antibiotics while introducing greater variety. Used in integrative medicine practice settings.

Evidence Summary

SIBO vs IBS: Distinguishing Features

Clinically distinguishing SIBO from IBS (without SIBO) matters because they respond to different interventions. Key differentiators:

• SIBO symptom onset: Typically post-infectious (after food poisoning, gastroenteritis, international travel). IBS can be insidious onset without clear precipitant.
• Response to fasting: SIBO symptoms often improve significantly during fasting periods (MMC activity increases; bacteria have no substrate). This fasting improvement is less pronounced in pure IBS.
• Nutrient malabsorption: Fat malabsorption, B12 deficiency, and fat-soluble vitamin deficiencies point toward SIBO rather than functional IBS
• Antibiotic history: Paradoxically, SIBO often worsens with broad-spectrum antibiotics that disrupt the colon but leave small bowel bacteria intact. Rifaximin is non-systemic and gut-selective.
• Post-meal timing: Bloating appearing 30–90 minutes after eating is characteristic of small intestinal fermentation timing. Later-onset bloating (2–3 hours post-meal) is more consistent with colonic fermentation.

Working with Your Doctor: Getting Tested

Breath testing for SIBO is available through several channels. Your gastroenterologist or functional medicine physician can order lactulose or glucose breath tests through major commercial labs (Genova Diagnostics, Doctor's Data, Commonwealth Diagnostics International, or the Trio-Smart 3-gas test through Gemelli Biotech). Some direct-to-consumer at-home breath test options exist but require clinical context for accurate interpretation.

Before your appointment, document:

1. When symptoms began and any possible precipitating events (food poisoning, antibiotic courses, surgery)
2. Bowel habit pattern (frequency, consistency, urgency)
3. Relationship between eating and symptom onset (timing)
4. Previous antibiotic or PPI use history
5. Response to dietary restriction (fasting, low-carb, low-FODMAP)